secwatch.observer — SEC 8-K summary
======================================

Issuer:     LifeMD, Inc. (LFMD)
CIK:        0000948320
Form:       8-K
Filed at:   2022-01-12T23:59:59+00:00
Accession:  0001493152-22-001058
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LifeMD acquires allergy telehealth platform Cleared; total consideration up to $76.7M
--------------------------------------------------------------------------------

- Upfront $460k cash + $3.46M milestone payments + up to $72.8M earn-out based on $150M revenue.
- Acquisition expected to close in Q1 2022; Cleared provides allergy/asthma telehealth in all 50 states.
- Deal expected to be accretive to LifeMD's Adjusted EBITDA in 2022 and significantly accretive thereafter.
- LifeMD also purchasing a $507k convertible note from a strategic pharma investor alongside the acquisition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/948320/000149315222001058/0001493152-22-001058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/948320/000149315222001058/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-001058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer